Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Regular Approval to Nivolumab for Adjuvant Treatment of Melanoma

It is approved for adjuvant treatment in patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection
03 Jan 2018
Melanoma and other skin tumours;  Cancer Immunology and Immunotherapy

On 20 December 2017, the US Food and Drug Administration (FDA) granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (OPDIVO, Bristol-Myers Squibb Company) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Nivolumab was previously approved for the treatment of patients with unresectable or metastatic melanoma.

Approval was based on improvement in recurrence-free survival (RFS) in a randomised, double-blind trial, CHECKMATE-238 (NCT02388906), in 906 patients with completely resected, stage IIIB/C or stage IV (AJCC 7th ed) melanoma. Patients were randomly allocated (1:1) to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses then every 12 weeks beginning at week 24 for up to 1 year. Enrolment required complete resection of melanoma with margins negative for disease within 12 weeks prior to randomisation.

The major efficacy outcome measure was RFS, defined as the time between the randomisation date and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death from any cause, whichever occurs first. Patients in the nivolumab arm experienced fewer recurrences/deaths, 34% (n = 154), compared with 45.5% (n = 206) in the ipilimumab arm (hazard ratio 0.65; 95% confidence interval 0.53, 0.80; p < 0.0001). Median RFS was not reached on either arm.

The median duration of nivolumab exposure was 11.5 months and 74% of patients received nivolumab for greater than 6 months. Nivolumab was discontinued for adverse reactions in 9% of patients.

The most common adverse reactions (reported in at least 20% of nivolumab-treated patients in CHECKMATE-238) were fatigue, diarrhoea, rash, musculoskeletal pain, pruritus, headache, nausea, upper respiratory infection, and abdominal pain. The most common immune-mediated adverse reactions were rash (16%), diarrhoea/colitis (6%), and hepatitis (3%).

The recommended dose and schedule of nivolumab in adjuvant melanoma is 240 mg administered as an i.v. infusion over 60 minutes every two weeks until disease recurrence or unacceptable toxicity, for a maximum of 1 year.

Full prescribing information is available here.  

FDA granted priority review to nivolumab for this application and granted the approval approximately eight weeks ahead of the goal date. Nivolumab was granted breakthrough therapy designation for this indication.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 03 Jan 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.